Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 4,170 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Terminated Phase 1Phase 2 Interventional Results available

MGC018 With or Without MGA012 in Advanced Solid Tumors

NCT03729596
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer
Interventions
vobramitamab duocarmazine
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
9
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 25, 2026, 4:14 AM EDT
Active, not recruiting Not applicable Interventional Results available

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

NCT04905082
View directory record Official record
Conditions
Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
Interventions
Best Practice, Educational Intervention, Genomic Profile, Survey Administration
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Terminated Phase 1 Interventional

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

NCT04931823
View directory record Official record
Conditions
Solid Tumor
Interventions
CPO-100
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer

NCT00786682
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, hydroxychloroquine
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
7
States / cities
Hamilton, New Jersey • Montclair, New Jersey • Morristown, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 25, 2026, 4:14 AM EDT
Terminated Phase 1Phase 2 Interventional

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

NCT06065059
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
Interventions
TNG348, Olaparib
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Denver, Colorado • Orange City, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 25, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

NCT00048659
View directory record Official record
Conditions
Hormone-Refractory Prostate Cancer, Prostatic Neoplasms
Interventions
YM598
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
14
States / cities
Anchorage, Alaska • San Bernardino, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 25, 2026, 4:14 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

NCT02489318
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Placebo, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
39
States / cities
Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Not applicable Interventional

Effects of GCP on Prostate Cancer.

NCT00269555
View directory record Official record
Conditions
Prostate Cancer
Interventions
Genistein Combined Polysaccharide (GCP)
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 1Phase 2 Interventional

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

NCT03543189
View directory record Official record
Conditions
Prostate Cancer, Prostate Disease
Interventions
Nivolumab, Brachytherapy, External Beam Radiation Therapy, Androgen Deprivation Therapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Terminated Phase 1 Interventional

A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

NCT04586270
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
TAS0612
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 3 Interventional

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

NCT00030654
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, flutamide, ketoconazole, paclitaxel, releasing hormone agonist therapy, vinblastine sulfate
Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
75
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Not applicable Interventional

Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer

NCT00060086
View directory record Official record
Conditions
Prostate Cancer
Interventions
pomegranate juice
Dietary Supplement
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 25, 2026, 4:14 AM EDT
Active, not recruiting Not applicable Interventional

Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA

NCT03234556
View directory record Official record
Conditions
Health Status Unknown, Elevated PSA
Interventions
Biopsy of Prostate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, MRI Ultrasound Fusion Guided Biopsy
Procedure · Other · Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
40 Years and older · Male only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Active, not recruiting Phase 1 Interventional

Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

NCT01140373
View directory record Official record
Conditions
Prostate Cancer
Interventions
engineered autologous T cells, cyclophosphamide
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Active, not recruiting Not applicable Interventional

Micro-UltraSound In Cancer - Active Surveillance

NCT05558241
View directory record Official record
Conditions
Prostate Cancer
Interventions
High-resolution micro-ultrasound
Device
Lead sponsor
University of Alberta
Other
Eligibility
18 Years and older · Male only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Not applicable Interventional

Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors

NCT00086762
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific, Breast Cancer, Gastrointestinal Cancer, Disease (or Disorder); Gynecological, Prostate Cancer
Interventions
MR Therapy, Relaxing Music (RM) Therapy, Standard Symptom Management, Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
9
States / cities
Wichita, Kansas • Ann Arbor, Michigan • Grand Rapids, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

Docetaxel and Lycopene in Metastatic Prostate Cancer

NCT01949519
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Lycopene and Docetaxel
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 25, 2026, 4:14 AM EDT
Recruiting Not applicable Interventional

Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer

NCT07219303
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
adaptive stereotactic body radiation therapy (SBRT) with a SIB
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 25, 2026, 4:14 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07214961
View directory record Official record
Conditions
Prostate Cancer (CRPC), Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions
AB001
Drug
Lead sponsor
ARTBIO Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Grand Rapids, Michigan • Omaha, Nebraska • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Recruiting Phase 1 Interventional

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

NCT04890613
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
CX-5461
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Santa Monica, California • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Completed No phase listed Observational

Optional Sub-study to Intraoperative Imaging With ICG Registry

NCT02651246
View directory record Official record
Conditions
Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer, Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
Interventions
data collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis

NCT00826514
View directory record Official record
Conditions
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions
Tanezumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

NCT03311555
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Androgen deprivation, Salvage radiation therapy, Docetaxel
Drug · Radiation
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Omaha, Nebraska • New York, New York • Cary, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 25, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

Fulvestrant in Treating Patients With Recurrent Prostate Cancer

NCT00217464
View directory record Official record
Conditions
Prostate Cancer
Interventions
fulvestrant
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 25, 2026, 4:14 AM EDT